Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473163 | 1.00 | SCN9A (0.40) | SCN9ARIPK1PRMT5WDR77CYP19A1 | |
| SCHEMBL22473473 | 1.00 | SCN9A (0.40) | SCN9ARIPK1PRMT5WDR77CYP19A1 | |
| SCHEMBL22473296 | 0.82 | RIPK1 (0.38) | RIPK1PRMT5WDR77CYP19A1CYP11B2 | |
| SCHEMBL22473380 | 0.81 | SCN9A (0.38) | SCN9ARIPK1PRMT5WDR77 | |
| SCHEMBL22473215 | 0.76 | PRMT5 (0.45) | RIPK1PRMT5WDR77CYP19A1CYP11B2 | |
| SCHEMBL22473352 | 0.76 | PRMT5 (0.45) | RIPK1PRMT5WDR77CYP19A1CYP11B2 | |
| SCHEMBL22473156 | 0.74 | SCN9A (0.42) | SCN9APRMT5WDR77 | |
| SCHEMBL22473186 | 0.73 | RIPK1 (0.40) | SCN9ARIPK1 | |
| SCHEMBL22473188 | 0.73 | RIPK1 (0.40) | SCN9ARIPK1 | |
| SCHEMBL22473175 | 0.73 | RIPK1 (0.40) | SCN9ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | SCN9A 256/4885RIPK1 3202/4885PRMT5 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.